Search results (159)
« Back to News & OpinionNews and Opinion from the Pandemic Sciences Institute at the University of Oxford
Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing
1 June 2026
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.
Media spotlight: PSI experts on Bundibugyo Ebola vaccines and treatments
28 May 2026
Several UK and global outlets have covered Oxford’s response to the Bundibugyo Ebola virus outbreak currently affecting the DRC and Uganda.
Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC
22 May 2026
In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.
UK launches a study of Andes hantavirus using a pre-approved outbreak protocol
21 May 2026
Study uses ISARIC's globally recognised Clinical Characterisation Protocol
Decentralising disease surveillance and modelling approaches will support equitable infectious disease responses
21 May 2026
By sharing data analytics instead of raw data, federated approaches enable surveillance and modelling while respecting ethical and legal boundaries.
Major European study warns current measures failing to halt spread of ‘superbugs’
14 May 2026
New data from 37 countries reveals the escalating threat of carbapenem-resistant K. pneumoniae and identifies ‘warning signals’ for E. coli, prompting calls for global genomic surveillance.
Improving early diagnosis of HIV and Hepatitis B and C with machine learning algorithms
12 May 2026
The BMC Infectious Diseases study is the first to investigate the integration of machine learning algorithms with primary care data to support testing for blood-borne diseases.
Media Spotlight: PSI experts comment on hantavirus outbreak
11 May 2026
PSI members have provided expert comment on the recent hantavirus outbreak across a range of media.
Three new Associate Professorships confirm PSI’s continued impact in research, teaching and service
11 May 2026
Announcement recognises colleagues’ significant and sustained contribution to the University of Oxford.
International Pandemic Sciences Conference 2026: strengthening preparedness and building resilience
30 April 2026
From 1 to 3 July 2026, the International Pandemic Sciences Conference will bring together leading scientists, policymakers, and practitioners in Singapore and online to explore how we can strengthen pandemic preparedness, resilience and equitable access to science.
Oxford and Serum Institute of India sign IP licence agreement to advance NipahB vaccine candidate
16 March 2026
The agreement will enable the Serum Institute of India to support the development, manufacture and potential future supply of the vaccine candidate developed by PSI scientists.
Epigames generate real-life insights to inform the future of pandemic preparedness
26 February 2026
Bringing together real environments and simulated outbreak scenarios, the epigames approach combines decision-making, real-time network dynamics and structured incentives.
Pandemic PACT launches new WHO Pandemic and Epidemic Intelligence Funding Tracker dashboard
17 February 2026
Pandemic and epidemic intelligence is essential for preventing, detecting and responding to current and future public health threats.
Two PSI members among the first Fellows of the Academy for the Mathematical Sciences
2 February 2026
The Academy for the Mathematical Sciences will bring together the UK’s strongest mathematicians across academia, education, business, industry, and government to help solve some of the UK’s biggest challenges.
New review provides insights to inform future Nipah virus clinical trials
30 January 2026
The review, which has been published in The Lancet Microbe, addresses critical knowledge gaps, helping to inform the design of future clinical trials and improve patient treatment.
PSI supports the 100 Days Mission Implementation Report’s call to reinvigorate pandemic preparedness research and development
28 January 2026
Several PSI activities and initiatives have been identified as contributing to the 100 Days Mission's goal to prepare as much as possible within the first 100 days of a pandemic.
Join us for the International Pandemic Sciences Conference 2026
23 January 2026
Co-hosted by PSI and Singapore’s Programme for Research in Epidemic Preparedness and REsponse (PREPARE), this year's conference will take place in Singapore and online from 1 to 3 July 2026.
New toolkit offers practical guidance to tackle stigma in infectious disease outbreaks
9 January 2026
Thirty international experts collaborated to produce the ISARIC Anti-Stigma Guidelines: a practical toolkit designed for use in outbreak response planning and delivery.
Ambitious research aiming to develop multivalent vaccines to protect against multiple deadly filoviruses
8 January 2026
Working with international partners, scientists across PSI and OVG will design and develop multivalent vaccine candidates with funding from CEPI and Horizon Europe.
Driving the development of new tools to combat Nipah virus outbreaks
18 December 2025
- Ethics, social science & humanities
- Nipah virus
- Pathogen biology & new threats
- Research news
- Vaccines, treatments, diagnostics & trials
PSI’s Nipah Virus Research Day, held on Wednesday, 19 November 2025, showcased promising developments, spanning new insights into Nipah virus biology, clinical trials of vaccines, the development of policy responses, and progress in developing diagnostics and treatments, all of which are helping improve responses to outbreaks of this deadly virus.